Liu et al. [19] conducted research assessing the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of CKD associated with diabetes mellitus type 2 (DM2). This evidence concerns the gene SLC5A2 and myotonic dystrophy type 2.